EGFR and non-small cell lung carcinoma: In a database of over 57 000 advanced NSCLC patients, FGFR2 and FGFR3 fusions were detected in 0.02% and 0.26%, respectively. FGFR3-TACC3 fusions account for over 91% of them, while fusions co-occurred with EGFR mutations in roughly 24% of cases.